propafenone has been researched along with Cardiomyopathies in 12 studies
Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.
propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias.
Cardiomyopathies: A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).
| Excerpt | Relevance | Reference |
|---|---|---|
| "This retrospective case series study sought to describe the safety and clinical effectiveness of propafenone for the control of arrhythmias in children with and without CHD or cardiomyopathy." | 4.12 | Electrophysiological effects and clinical utility of propafenone in children. ( Ferns, SJ; Gehi, AK; Hudak, ML; McKenzie, K; Singh, M, 2022) |
| "With flecainide, nine cases were reported at varying times after initiation of therapy, from in-hospital to 8 months." | 2.39 | Inpatient versus outpatient initiation of antiarrhythmic drug therapy for patients with supraventricular tachycardia. ( Prystowsky, EN, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (8.33) | 18.7374 |
| 1990's | 5 (41.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Singh, M | 1 |
| McKenzie, K | 1 |
| Hudak, ML | 1 |
| Gehi, AK | 1 |
| Ferns, SJ | 1 |
| Hyman, MC | 1 |
| Mustin, D | 1 |
| Supple, G | 1 |
| Schaller, RD | 1 |
| Santangeli, P | 1 |
| Arkles, J | 1 |
| Lin, D | 1 |
| Muser, D | 1 |
| Dixit, S | 1 |
| Nazarian, S | 1 |
| Epstein, AE | 1 |
| Callans, DJ | 1 |
| Marchlinski, FE | 1 |
| Frankel, DS | 1 |
| Capucci, A | 1 |
| Ciliberti, G | 1 |
| Guerra, F | 1 |
| Vallurupalli, S | 1 |
| Pothineni, NV | 1 |
| Deshmukh, A | 1 |
| Paydak, H | 1 |
| Ge, H | 1 |
| Li, X | 1 |
| Liu, H | 1 |
| Jiang, H | 1 |
| Hasdemir, C | 1 |
| Musayev, O | 1 |
| Kehribar, DY | 1 |
| Kartal, Y | 1 |
| Can, LH | 1 |
| Prystowsky, EN | 1 |
| Oliveira, M | 1 |
| da Silva, N | 1 |
| Antunes, E | 1 |
| Pinto, E | 1 |
| Cotrim, C | 1 |
| Pitta, L | 1 |
| Cacela, D | 1 |
| Gracias, R | 1 |
| Antunes, AM | 1 |
| Gillis, AM | 1 |
| Lester, WM | 1 |
| Keashly, R | 1 |
| Healy, B | 1 |
| Villain, E | 1 |
| Bonnet, D | 1 |
| Kachaner, J | 1 |
| Le Bidois, J | 1 |
| Cohen, L | 1 |
| Piéchaud, JF | 1 |
| Sidi, D | 1 |
| Kasanuki, H | 1 |
| Onishi, S | 1 |
| Hirosawa, K | 1 |
3 reviews available for propafenone and Cardiomyopathies
| Article | Year |
|---|---|
Inpatient versus outpatient initiation of antiarrhythmic drug therapy for patients with supraventricular tachycardia.
Topics: Ambulatory Care; Anti-Arrhythmia Agents; Cardiomyopathies; Flecainide; Hospitalization; Humans; Prop | 1994 |
[Guided anti-arrhythmia therapy by programmed ventricular stimulation. A case of arrhythmogenic dysplasia of the right ventricle].
Topics: Adult; Anti-Arrhythmia Agents; Biopsy; Cardiac Pacing, Artificial; Cardiomyopathies; Endocardium; Fe | 1997 |
[Incessant idiopathic ventricular tachycardia in infants].
Topics: Amiodarone; Cardiomyopathies; Child, Preschool; Electrocardiography; Female; Flecainide; Follow-Up S | 1990 |
9 other studies available for propafenone and Cardiomyopathies
| Article | Year |
|---|---|
Electrophysiological effects and clinical utility of propafenone in children.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiomyopathies; Child, Preschool; Coronary Disease; | 2022 |
Class IC antiarrhythmic drugs for suspected premature ventricular contraction-induced cardiomyopathy.
Topics: Anti-Arrhythmia Agents; Cardiomyopathies; Echocardiography; Electrocardiography; Female; Flecainide; | 2018 |
To the Editor- Flecainide and propafenone: Good twins for premature ventricular contractions' killing but not exactly superimposable.
Topics: Anti-Arrhythmia Agents; Cardiomyopathies; Flecainide; Humans; Propafenone; Ventricular Premature Com | 2018 |
Utility of Routine Exercise Testing to Detect Rate-Related QRS Widening in Patients Without Structural Heart Disease on Class Ic Antiarrhythmic Agents (Flecainide and Propafenone).
Topics: Arkansas; Cardiomyopathies; Echocardiography; Electrocardiography; Exercise Test; Female; Flecainide | 2015 |
Predictors of Pharmacological Therapy of Ectopic Atrial Tachycardia in Children.
Topics: Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathies; Child; Child, Preschool; China; Drug Therapy, | 2017 |
Chronic cough and tachycardia-induced cardiomyopathy in a patient with idiopathic frequent, monomorphic premature ventricular contractions.
Topics: Aged; Anti-Arrhythmia Agents; Cardiomyopathies; Chronic Disease; Cough; Female; Humans; Propafenone; | 2013 |
Propafenone disposition and pharmacodynamics in normal and norepinephrine-induced cardiomyopathic rabbit hearts.
Topics: Animals; Cardiomyopathies; Dose-Response Relationship, Drug; Electrocardiography; Heart Conduction S | 1991 |
From the National Institutes of Health.
Topics: Acute Disease; ADP Ribose Transferases; Amoxicillin; Arrhythmias, Cardiac; Bacterial Toxins; Cardiom | 1991 |
The usefulness of electrophysiological-pharmacologic studies in the long-term therapy of paroxysmal tachycardias.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Cardiomyopathies; Chromatogra | 1985 |